Revvity Pk 11195, -, 250µci (9.25mbq)

Revvity 250 µCi quantities of PK 11195, [N-Methyl-³H]-, are available for your research. PK-11195 acts as an antagonist at peripheral benzodiazepine receptors (PBRs), and is used as a marker of neuronal damage in animal models of central nervous system (CNS) damage. PBRs are potential drug targets for cancer, autoimmune, infectious disease, and neurodegenerative disease. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET885: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

V Papadopoulos, P Guarneri, K E Kreuger, A Guidotti, and E Costa. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. PNAS, vol. 89, no. 11, 1992, Pages 5113-5117.Benavides, J., Quarteronet, D., Plouin, P., Imbault, F., Phan, T., Uzan, A., Renault, C., Dubroeucq, M., Gueremy, C., Le Fur, g. Characterization of peripheral type benzodiazepine binding sites in human and rat platelets by using [3H]PK 11195. Studies in hypertensive patients, Biochemical Pharmacology, vol 33, issue 15, 1984, Pages 2467-2472.